FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

$\overline{}$	Check this box if no longer subject to Section 16. Form 4
1 1	F F II

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						or Sectio	n 30(h) of the	Investme	nt Comp	any Act of	1940								
Name and Address of Reporting Person*     Carino Tanisha					2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS, INC. [ ALXN ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director				10% Own	er
,															Officer (give title below) Other (spec			ecify below)	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)									EVP & CCAO					
C/O ALEXION PHARMACEUTICALS, INC.					11/29/2019														
121 SEAPORT BOULEVARD																			
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6.	6. Individual or Joint/Group Filing (Check Applicable Line)					
BOSTON M.	A	02:	210										X	X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
															Form filed by Mo	re than Or	ne Repor	ting Person	
(City) (St	ate)	(Zip	D)																
			7	Table I -	Non-Deri	ivative Se	curities A	quired	, Disp	osed of	, or Bene	ficially Ov	vned						
1. Title of Security (Instr. 3)					2. Transacti					4. Securit	Securities Acquired (A) or Disposed Of (D)			D) (Instr. 5. Amount of Securities Beneficially Owned Fo					7. Nature of Indirect Beneficial Ownership (Instr. 4)
			(Month/Day	/Year)   if any	) if any		· · · ·		Amount (A) or (D)		Price	Re	Reported Transaction (Instr. 3 and 4)		s) (Instr. 4)				
C					11/20/2	<u> </u>	Dayrica.y	A	Ė	_	777(1)	A	\$0	- (	8,777			D	
Common Stock, par value \$.0001 per share						11/29/2019		А		8,777(1)		A	Φ0		0,///		D		
				Table I		ative Secu puts, calls							ed						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		4. Transad (Instr. 8)	ction Code	Securities A	ber of Derivative ies Acquired (A) or ed of (D) (Instr. 3, 4		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Derivative Security (Instr. 3 and 4)					9. Number derivative Securitie Beneficia Owned Following	ive Form (D) or cially (I) (In:	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security				v	(A)	(D)	Date Exercis	Date Ex Exercisable Da				Amount Number	or of Shares		Reported Transaction(s) (Instr. 4)			

Explanation of Responses:

1. Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date.

## Remarks:

/s/ Douglas Barry, Attorney-in-Fact for Tanisha <u>12/02/2019</u>

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\* If the form is filed by more than one reporting person, see Is U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

### POWER OF ATTORNEY

Known all by these presents, that the undersigned hereby constitutes and appoints William Wheeler and Douglas Barry, each signing singly, the undersigned's true

- (1) Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Alexion Pharmaceuticals, Inc. (the "Company"), Forms
- (2) Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4, 5 (or any 5
- (3) Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best:

  The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necess.

  This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5 (or any successor forms) and any

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of October, 2019.

/s/ Tanisha Carino (signature)

Tanisha Carino